{
    "clinical_study": {
        "@rank": "66938", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single dose, open-label, randomized, crossover study in subjects with severe\n      Hemophilia A to compare the bioavailability of 2 different strengths of Kogenate FS (BAY\n      14-2222)."
        }, 
        "brief_title": "Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males, age 18 to 65 years\n\n          -  Subjects with Severe hemophilia A with a documented plasma FVIII level of <1%\n\n          -  >/= 150 ED (exposure days) with FVIII concentrates(s) as supported by medical records\n\n        Exclusion Criteria:\n\n          -  Evidence of current or past inhibitor antibody\n\n          -  History of any congenital or acquired coagulation disorders other than hemophilia A\n\n          -  Platelet count <75,000/mm3\n\n          -  Abnormal renal function (serum creatinine >2 times the upper limit of the normal\n             range)\n\n          -  Active liver disease verified by medical history or persistently elevated alanine\n             aminotransferase (ALT) or aspartate aminotransferase (AST) >5x the upper limit of\n             normal or severe liver disease as evidenced by, but not limited to any of the\n             following: International Normalized Ratio (INR) >1.4, hypoalbuminemia, portal vein\n             hypertension including presence of otherwise unexplained splenomegaly and history of\n             esophageal varices"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01653639", 
            "org_study_id": "15495", 
            "secondary_id": "2012-001045-40"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm 1", 
                "description": "50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)", 
                "intervention_name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "description": "50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)", 
                "intervention_name": "Recombinant Factor VIII (Kogenate FS, BAY14-2222)", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "BAY14-2222", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "January 8, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Sofia", 
                    "country": "Bulgaria", 
                    "zip": "1756"
                }
            }
        }, 
        "location_countries": {
            "country": "Bulgaria"
        }, 
        "number_of_arms": "2", 
        "official_title": "Single Dose, Open-label, Randomized, Crossover Study in Subjects With Severe Hemophilia A to Compare the Bioavailability of 2 Different Strengths of Kogenate FS (BAY14-2222)", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Bulgaria: Bulgarian Drug Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum plasma concentration (Cmax) of BAY14-2222", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours"
            }, 
            {
                "measure": "Area under the plasma concentration vs time curve from time 0 to time of last measurable concentration  AUC(0-tlast) of BAY14-2222", 
                "safety_issue": "No", 
                "time_frame": "Up to 48 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01653639"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}